The Ontario Institute for Cancer Research (OICR) is a leading research organization dedicated to advancing cancer research and developing real-world solutions to improve the lives of those affected by cancer. OICR operates in the life sciences sector, focusing on areas such as genomics, informatics, diagnostic development, drug discovery, immuno-oncology, and imaging. The institute collaborates with top researchers and institutions across Ontario and globally, leveraging a multi-institutional model to drive innovation and translational research. OICR serves a diverse range of clients, including cancer patients, healthcare providers, and biotechnology startups. The organization generates revenue through a combination of public funding, private investments, and partnerships with industry stakeholders. OICR's business model emphasizes collaboration and investment in early-stage biotechnology companies, helping them advance their cancer innovations from concept to market. The institute's investment programs have successfully attracted significant funding to the life sciences sector, with a portfolio of biotechnology startups that have collectively raised $1.5 billion in 2023. This milestone represents a 30-fold leverage from the private sector for FACIT investments, highlighting OICR's impact on the local and global cancer research landscape.

Keywords: cancer research, genomics, informatics, diagnostics, drug discovery, immuno-oncology, imaging, biotechnology, investment, translational research.